Efficacy of Helicobacter pylori eradication followed by sequential administration of proton pump inhibitor and proton pump inhibitor plus prokinetic for the patients with dyspepsia

Efficacy of Helicobacter pylori eradication followed by sequential administration of proton pump inhibitor and proton pump inhibitor plus prokinetic for the patients with dyspepsia - Efficacy of H.pylori eradication, PPI, and PPI plus prokinetic for dyspepsia

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000012827

Enrollment

200

Registered

2014-01-14

Start date

2014-01-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients with dyspepsia and H.pylori infection

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) the subjects complaining of dyspepsia with gastritis diagnosed by EGD and H.pylori infection 2) the subjects with written informed consent

Exclusion criteria

Exclusion criteria: 1) patients with past history of gastrectomy 2) patients with alarm symptom auch as vomiting, gastrointestinal hemorrhage, and rapid body weight loss 3) reflux esophagitis (> and = Los Angeles grade A) or peptic ulcer 4) patients with the following diseases or previous history: Zollinger-Ellison syndrome; inflammatory bowel disease; esophageal stenosis; Achalasia; and organic disease in the brain 5) severe diseases in liver, kidney, and heart 6) persons with malignancy or possibility of malignancy 7) expect muther, mother with breast-feeding 8) under administration of atazanavir sulfate 9) drug allegy for penicillin 10) administration the following drugs within 2 weeks: proton pump inhibitors; histamine 2-receptor antagonists; and prokinetics 11) other not applicable person recognized by a doctor

Design outcomes

Primary

Measure	Time frame
1) overall evaluation for each treatment by patients 2) evaluation of symptom index (modified F scale) at baseline, post 4 weeks treatment of rabeprazole, and post 4 weeks treatment of rabeprazole plus acotiamide	—

Secondary

Measure	Time frame
1) assessment of the symptom factors that influence the efficacy during the treatment from the symptom index (modified F scale) 2) patients'QOL by using SF 8 scale at baseline, post 4 weeks treatment of rabeprazole, and post 4 weeks treatment of rabeprazole plus acotiamide	—

Countries

Japan

Contacts

Public ContactHiroyuki Okada

Okayama University Hospital Department of Endoscopy

hiro@md.okayama-u.ac.jp086-235-7218

Outcome results